Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Other · Morgan Stanley

Vitality Portfolio Class A (MSVEX)

Ticker MSVEX ·

Expense ratio
1.3%$130/yr per $10k
1-yr return
+8.7%as of Dec 2025

Bottom line

Is MSVEX a good fund? The bottom line

MSVEX is the Class A share class of Vitality Portfolio, a managed other mutual fund from Morgan Stanley.

It charges 1.3% — about $130 a year on every $10,000 invested, more expensive than 92% of other funds we track.

It returned +8.7% over one year (as of Dec 31, 2025, per its prospectus).

This share class carries a front-end sales charge of up to 5.25%; a no-load class or ETF alternative can avoid it.

What to watch

  • Expensive for its category (1.3%)
  • Front-end sales load up to 5.25%
  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What MSVEX invests in

The Vitality Portfolio (the Fund) seeks long-term capital appreciation.

Under normal market conditions, the Adviser seeks to achieve the Funds investment objective by investing primarily in securities of companies located in the United States that are principally engaged in the discovery, development, production, or distribution of products or services related to advances in healthcare. These companies include, but are not limited to, biotechnology, pharmaceuticals, medical equipment and supplies, healthcare technology, healthcare providers and services, and life sciences tools and services. The Fund may also allocate to industries related to the healthcare industry, but are not primarily engaged in the scientific advancement of healthcare. The allocation among these areas will vary depending on the relative potential the Adviser sees within each area and the outlook for the overall healthcare sector. ? The Adviser emphasizes a bottom-up stock selection…

From the fund's prospectus (filed Apr 30, 2026).

MSVEX performance

Average annual total returns
1 yr5 yr10 yr
MSVEX+8.7%——
Other median+9.2%+4.9%+5.3%

Source: Fund prospectus, as of Dec 31, 2025

Full MSVEX performance history →

What MSVEX costs

On a $10,000 investment, MSVEX's 1.3% expense ratio costs about $130 a year. The prospectus estimates $10,017 in total costs over 10 years (assuming 5% annual returns). The median other fund charges 0.95%.

See the full MSVEX fee table →

Alternatives to MSVEX

More funds like MSVEX →

MSVEX FAQ

What is the expense ratio of MSVEX?
MSVEX's expense ratio is 1.3%, which works out to about $130 a year for every $10,000 invested. The prospectus estimates total costs of $10,017 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is MSVEX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.3%); front-end sales load up to 5.25%; 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
Does MSVEX have a sales load?
Yes. MSVEX has a maximum front-end sales charge of 5.25%. It may charge a deferred sales charge of up to 1% if sold early.
Who manages MSVEX?
MSVEX is offered by Morgan Stanley through Morgan Stanley Institutional Fund Inc.